ePedigree Requirements to Take a Few More Years - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePedigree Requirements to Take a Few More Years


ePT--the Electronic Newsletter of Pharmaceutical Technology

Sacramento, CA (Oct. 9)—The electronic pedigree mandate for prescription drugs has been delayed again. California Gov. Arnold Schwarzenegger signed legislation that delays ePedigree implementation until 2015.

The deadline was first pushed back last March, from January 2009 to January 2011. Now, manufacturers will have another few years to comply with the new requirement.

Under the act, S.B. 1307, a manufacturer selling drugs in California must have an ePedigree for 50% of the drugs it sells in the state by 2015. As of July 2016, wholesalers or repackagers will be prohibited from selling, trading, or transferring a dangerous drug without a pedigree or from acquiring a dangerous drug without receiving a pedigree; the same rule will go into effect for pharmacies in July 2017. A pharmacy warehouse will not be able to acquire a dangerous drug without receiving a pedigree, as of July 2017.

Industry has been keeping an eye on California’s ePedigree rules as they are likely to impact all US manufacturers and set the stage for a national ePedigree standard. It now looks like companies have more than enough time to prepare.

Read the full legislation here.

Read more about ePedigrees:

ePedigree: Using the Gift of Time Wisely

Epedigree in the Pharmaceutical Supply Chain

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here